Neuropathic pain genesis is related to gene alterations in the dorsal root ganglion (DRG) after peripheral nerve injury. Transcription factors control gene expression. In this study, we investigated whether octamer transcription factor 1 (OCT1), a transcription factor, contributed to neuropathic pain caused by chronic constriction injury (CCI) of the sciatic nerve. Chronic constriction injury produced a time-dependent increase in the level of OCT1 protein in the ipsilateral L4/5 DRG, but not in the spinal cord. Blocking this increase through microinjection of OCT1 siRNA into the ipsilateral L4/5 DRG attenuated the initiation and maintenance of CCI-induced mechanical allodynia, heat hyperalgesia, and cold allodynia and improved morphine analgesia after CCI, without affecting basal responses to acute mechanical, heat, and cold stimuli as well as locomotor functions. Mimicking this increase through microinjection of recombinant adeno-associated virus 5 harboring full-length OCT1 into the unilateral L4/5 DRG led to marked mechanical allodynia, heat hyperalgesia, and cold allodynia in naive rats. Mechanistically, OCT1 participated in CCI-induced increases in Dnmt3a mRNA and its protein and DNMT3a-mediated decreases in Oprm1 and Kcna2 mRNAs and their proteins in the injured DRG. These findings indicate that OCT1 may participate in neuropathic pain at least in part by transcriptionally activating Dnmt3a and subsequently epigenetic silencing of Oprm1 and Kcan2 in the DRG. OCT1 may serve as a potential target for therapeutic treatments against neuropathic pain.
Introduction
Peripheral nerve injury-induced neuropathic pain often occurs after surgery.
14 Despite concerted efforts to study, treat, and prevent neuropathic pain, effective treatment of this disorder remains relatively unsuccessful. 5, 14 Treating neuropathic pain often involves opioids, the most potent class of drugs used for relieving surgical pain. 21 Nearly 45% of patients prescribed opioids report inadequate pain relief, leading to the enhanced concerns in both patients and physicians for opioid addition. 15 In the United States, increases in opioid prescriptions over past decades have been accompanied by a huge increase in the incidence of addition and opioid-related mortality that constitutes the current "opioid crisis." 15 Therefore, further understanding the mechanisms of how peripheral nerve injury produces the development and maintenance of neuropathic pain may open a new avenue in the management of this disorder.
Neuropathic pain is characterized with pain in response to innocuous stimuli (allodynia), an enhanced response to noxious stimuli (hyperalgesia) and spontaneous pain. Abnormal hyperexcitability and ectopic discharges in neuronal cell bodies of the dorsal root ganglion (DRG) as well as neuroma at the sites of peripheral nerve injury are considered to be one of the primary causes of these pain hypersensitivities under neuropathic pain conditions. 1, 2 Abnormal hyperexcitability is likely attributed to peripheral nerve injurycaused alterations in gene transcription and translation in the DRG.
2,9,13 DNA methylation controls gene expression. Recently, accumulating evidence reveals that DNA methylation in the DRG participates in the mechanisms that underlie neuropathic pain genesis. An increase in the level of DNA methyltransferases 3a (DNMT3a) after unilateral fifth lumbar (L5) spinal nerve ligation (SNL) contributes to DNA hypermethylation at some CpG sites within the promoter regions of Oprm1 and Kcna2 genes, resulting in their expressional silencing in the DRG. 20, 26, 28 Blocking this increase through pharmacological inhibition or genetic knockdown of DRG DNMT3a attenuates nerve injury-induced pain hypersensitivities through rescuing the downregulation of DRG Oprm1 and Kcna2 genes. 20, 26, 28 DNMT3a in the DRG is likely an important player in the genesis of neuropathic pain.
A transcription factor octamer transcription factor 1 (OCT1) can bind to the "ATTTGCAT" sequence. 16 The promoter region of the Dnmt3a gene contains this consensus binding motif. 26 OCT1 increases the activity of this promoter in HEK-293 cells. 26 Spinal nerve ligation increases the expression of OCT1 and the binding activity of OCT1 to the promoter region of the Dnmt3a gene in the ipsilateral L5 DRG. 26 OCT1 overexpression leads to an increase in the expression of DNMT3a in DRG neurons. 26 Given that DNMT3a is an endogenous trigger of neuropathic pain, 26 DRG OCT1 may contribute to neuropathic pain.
In this study, we first examined whether the level of OCT1 expression increased in the ipsilateral DRG after chronic constriction injury (CCI) of unilateral sciatic nerve. We then characterized cellular expression and distribution patterns of OCT1 in the DRG of normal and CCI rats. We also examined whether blocking the increased DRG OCT1 alleviated CCI-caused pain hypersensitivities and whether mimicking CCI-caused increase in DRG OCT1 led to neuropathic pain symptoms. Finally, we observed whether these effects were mediated through OCT1 regulation of DNMT3a-triggered Oprm1 and Kcna2 gene expression in the DRG.
Materials and methods

Animal preparation
Adult male Sprague-Dawley rats (220-250 g; Charles River Lab, Wilington, MA and the laboratory animal center of Zhengzhou University, Zhengzhou, Henan province, China) were prepared as described previously. 25, 26 All animal procedures were approved by the Animal Care and Use Committee at the University of Zhengzhou and the Rutgers New Jersey Medical School and ethical guidelines of the International Association for the Study of Pain and the US National Institutes of Health. Efforts were made to ensure minimal animal use and discomfort. All experiments were performed by the investigators blinded to group assignments and treatment conditions.
Neuropathic pain model
Chronic constriction injury model was established as described previously. 6, 7 Briefly, 4-0 chromic gut thread was used to loosely ligate the left sciatic nerve at 4 sites with an interval of 1 mm around the nerve proximal to its trifurcation. Sham surgery was performed by exposing the sciatic nerve without ligation. Only rats without any abnormality were included in this study.
Morphine-induced analgesia
Morphine analgesia was established in rats as described previously. 10, 11 In brief, the morphine (1.5 mg/kg; WEST-WARD, Eatontown, NJ) was injected subcutaneously (s.c.) 3 days after CCI or sham surgery. The heat test as described below was conducted before surgery (baseline latency) and 30 minutes after morphine injection (response latency). The cutoff time was 20 seconds to avoid tissue damage. The percentage of maximal possible analgesic effect (% MPAE) was calculated as follows: % MPAE 5 ([response latency 2 baseline latency]/[cutoff time 2 baseline latency]) 3 100%. In addition, a peripheral MOR antagonist methylnaltrexone bromide (5 mg/kg, dissolved in saline; Medchemexpress USA, Monmouth Junction, NJ) was administered intraperitoneally (i.p.) 4 days after CCI or sham surgery. The heat test was conducted 1 day before CCI or sham surgery, 3 days after CCI or sham surgery, and before and 30 minutes after drug or saline administration on day 4 after CCI or sham surgery.
Dorsal root ganglion microinjection
Dorsal root ganglion microinjection was performed according to our previous studies. 4, 6, 7, 27 In brief, after the incision of lower lumbar back in the midline region was made, the unilateral L 4/5 DRG was exposed and received the injection of the virus (1-1.5 mL, 7.3 3 10 12 ), phosphate-buffered saline (1-1.5 mL), OCT1 siRNA (1-1.5 mL, 20 mM; Santa Cruz Biotechnology, Inc, Dallas, TX), or negative control siRNA (1-1.5 mL, 20 mM; Santa Cruz Biotechnology, Inc) with a glass micropipette (tip diameter 20-40 mm) connected to a Hamilton syringe. To avoid degradation and improve cell membrane penetration of siRNA, the delivery vehicle TurboFect in vivo transfection reagent (Thermo Scientific, Inc, Pittsburgh, PA) was used as described previously. 4, 6, 7, 27 After injection, the glass micropipette was remained at least for 10 minutes. Finally, the wound clips were used to close the skin incision. The injected rats showing the signs of paresis or other abnormalities were excluded from the study.
Behavior tests
The mechanical test was conducted as reported previously. 4, 24, 26, 27 The up-down testing paradigm was used to measure paw withdrawal thresholds (PWTs) in response to mechanical stimuli. Based on a formula provided by Dixon, 3 PWT was computed through conversion of the pattern of positive and negative responses into a 50% threshold value. The heat test was performed as described previously. 4, 24, 26, 27 The Model 336 Analgesia Meter (IITC Inc Life Science Instruments, Woodland Hills, CA) was used to measure paw withdrawal latencies (PWLs) to noxious heat. To avoid a burn injury, 20 seconds was used as a cutoff time. Each animal had 5 trials with a 5-minute interval per side. The mean value was calculated for the analysis. The cold test was performed as reported previously. 4, 24, 26, 27 A thermometer-monitored cold aluminum plate was used to measure PWLs to noxious cold stimulation. Each animal had 3 trials with a 10-minute interval on the ipsilateral side. To avoid tissue damage, 60 seconds was used as a cutoff time. The locomotor function test was performed based on the protocols reported previously. 4, 24, 26, 27 The placing, righting, and grasping reflexes were performed before tissue collection or rat euthanization. The counts of each reflex displayed in 5 trials were scored.
Western blot analysis
Protein extraction and Western blot analysis were performed as reported previously. 4, 24, 26, 27 Briefly, the tissue was homogenized on the ice with the lysis buffer. The pellet (nuclear fraction) and the supernatant (membrane/cytosolic fractions) were collected after centrifugation at 4˚C for 15 minutes at 1000g. The lysis buffer containing 2% sodium dodecyl sulfate and 0.1% Triton X-100 was used to dissolve the pellet. After being heated at 99˚C for 5 minutes, the samples (20 mg/sample) were loaded onto a 4% stacking/7.5% separating sodium dodecyl sulfatepolyacrylamide gel (Bio-Rad Laboratories, Hercules, CA) and then electrophoretically transferred onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories). The membranes were incubated first in the blocking buffer (3% nonfat milk plus 0.1% Tween-20 in the Tris-buffered saline) for 2 hours at room temperature and then in the primary antibodies at 4˚C overnight. The primary antibodies include: monoclonal rabbit anti-OCT1 (1: 1,200; Abcam, Cambridge, United Kingdom), mouse anti-Kv1.2 (1:1,000; NeuroMab, Davis, CA), rabbit anti-DNMT3A (1:1,000; Cell Signaling), rabbit anti-MOR (1:500, Neuromics, Edina, MN), rabbit anti-phosphorylated extracellular signal-regulated kinase (p-ERK1/2, 1:1,000, Cell Signaling), rabbit anti-extracellular signal-regulated kinase (ERK1/2, 1:1,000, Cell Signaling), mouse anti-glial fibrillary acidic protein (GFAP, 1:1,000, Cell Signaling), rabbit anti-histone H3 (1:1,000, Cell Signaling), and rabbit anti-GAPDH (1:1,000; Santa Cruz). After the membranes were incubated with the horseradish peroxidase-conjugated antirabbit or anti-mouse secondary antibody (1:3,000; Bio-Rad Laboratories) at room temperature for 1 hour, the enhanced chemiluminescence reagent (Bio-Rad Laboratories) was used to visualize the proteins. ChemiDoc XRS and System with Image Lab software (Bio-Rad Laboratories) were performed to generate the images. System with Image Lab software (Bio-Rad Laboratories) was performed to quantify to image intensities. The band intensities for cytosol proteins were normalized to GAPDH and those for nucleus proteins were normalized to H3.
Immunofluorescence histochemistry
The single-or double-label immunofluorescence histochemistry was performed as described previously. 4, 24, 26, 27 Briefly, after the rats were transcardially perfused, the L4/5 DRG was collected. The DRG were sectioned into 20 mm at the thickness. The sections were incubated in the blocking buffer (0.01M phosphate-buffered saline containing 0.3% Triton X-100 and 3% goat serum) for 1 hour at room temperature. For single-label immunofluorescence histochemistry, the sections were incubated alone with monoclonal rabbit anti-OCT1 ( 
Quantitative real-time reverse transcription polymerase chain reaction
Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) was performed as described previously. 4, 24, 26, 27 Briefly, the extracted RNA was reverse-transcribed with either specific reverse primers or the oligo (dT) primers (supplemental Table 1 , available at http://links.lww.com/PAIN/A664). The cDNA (1 mL) was amplified by real-time PCR with the primers indicated in supplemental Table 1 (http://links.lww.com/PAIN/A664). GAPDH as an internal control was used. A 20 mL reaction containing 20 ng of cDNA, 10 mL of SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories), and 200 nM forward and reverse primers was prepared. The triplicate reactions from each sample were performed in a BIO-RAD CFX96 real-time PCR system. The PCR cycle parameters consist of an initial 3-minute incubation at 95˚C, followed by 35 cycles of 95˚C for 10 seconds, 58˚C for 30 seconds, and 72˚C for 30 seconds. All results were normalized to GAPDH, as peripheral nerve injury does not alter its expression. 4, 24, 26, 27 The 4Ct method (2 244Ct ) was used to calculate the ratios of mRNA levels on the ipsilateral side to ones on the contralateral side.
Plasmid constructs and virus preparation
The SuperScript III One-Step RT-PCR System with the Platinum Taq High Fidelity Kit (Invitrogen) was used to reversely transcribe rat Oct1 full-length mRNA extracted from the rat DRG using the primers listed in supplementary Table 1 (http://links.lww.com/PAIN/A664) (Integrated DNA Technologies). After nested PCR using the primers listed in supplementary Table 1 (available at http://links.lww.com/ PAIN/A664) and Platinum Pfx DNA Polymerase (Invitrogen), the OCT1 coding sequences were amplified and digested by BspEI and NotI (New England Biolabs, Beverly, MA), followed by gel purification and ligation into proviral plasmids. The full length of OCT1 coding sequences were validated by sequencing. The control plasmid harboring enhanced green fluorescent protein (EGFP) was prepared in parallel. Recombinant adeno-associated virus 5 (AAV5) particles were packaged at the UNC Vector Core.
Statistical analysis
All data were analyzed by SigmaPlot 12.5. One-way or 2-way analysis of variance (ANOVA) with the post hoc Tukey testing and paired or unpaired Student t test were applied for normally distributed data and the Mann-Whitney U test was used for nonparametric data. The level of significance was set at P , 0.05. Data are present as mean 6 SEM.
Results
Chronic constriction injury increased OCT1 expression in the injured dorsal root ganglion
We first observed whether OCT1 expression was changed in the DRG and spinal cord dorsal horn, 2 major pain-related regions, under CCI-induced neuropathic pain conditions. The expression of OCT1 protein was time dependently increased in the ipsilateral L4/5 DRG after CCI, but not sham surgery (Figs. 1A and B) . As expected, CCI did not produce any alterations in the basal expression of OCT1 protein in the contralateral L4/5 DRG (data not shown). Chronic constriction injury also did not significantly alter OCT1 protein expression in the ipsilateral L4/5 spinal cord dorsal horn (Fig. 1C) .
We further examined the distribution pattern of OCT1 in the DRG. OCT1 colocalized with NeuN (a specific neuronal marker, Fig. 2A ) and with GS (a marker for satellite glial cells, Fig. 2B ). .8% were medium (600-1200 mm 2 in area), and 21.2% were small (,600 mm 2 in area; Fig. 2C ). Further analysis showed that approximately 43.5% of OCT1-labeled cells were labeled for NF200 (a marker for medium/large neurons and myelinated Ab fibers; Fig. 2D ), 33.3% were labeled for IB4 (a marker for small nonpeptidergic neurons; Fig. 2E) , and 42.9% were labeled for CGRP (a marker for small DRG peptidergic neurons; Fig. 2F ). Consistent with the observations by Western blot analysis above, on day 7 after CCI, the number of OCT1-labeled cells in the ipsilateral L4/5 DRG was 1.81-fold higher than the one in the contralateral L3/4 DRG (Figs. 2G and H) .
Effect of blocking increased dorsal root ganglion OCT1 on the induction of chronic constriction injury-caused pain hypersensitivity
Next, we investigated whether blocking the CCI-caused increase in DRG OCT1 through premicroinjecting OCT1 siRNA into the ipsilateral L4/5 DRG changed the induction of CCI-caused pain hypersensitivities. As expected, the amounts of OCT1 mRNA and protein were markedly increased in the ipsilateral L4/5 DRG on day 5 after CCI in rats premicroinjected with either vehicle or control negative siRNA (Figs. 3A and B) . These increases were absent in the CCI rats premicroinjected with OCT1 siRNA (Figs. 2A and B) . No significant decreases in basal amounts of OCT1 mRNA and protein were seen in the ipsilateral L4/5 DRG of the sham rats premicroinjected with OCT1 siRNA (Figs. 2A and B) . Behaviorally, the CCI rats premicroinjected with the vehicle displayed the enhanced paw withdrawal responses to mechanical, heat, and cold stimuli on the ipsilateral side (Figs. 2C-E) . On days 3 and 5 after CCI, the PWTs in response to mechanical stimulation (Fig. 3C ) and the PWLs in response to heat (Fig. 3D) and cold (Fig. 3E) stimuli, respectively, applied to the ipsilateral hind paw were markedly reduced as compared to presurgical baseline values. By contrast, the CCI rats premicroinjected with OCT1 siRNA failed to exhibit the augmented paw withdrawal responses to mechanical, heat, and cold stimuli on days 3 and 5 after CCI as compared to presurgical baseline values (Figs. 3C-E) . As expected, premicroinjection of OCT1 siRNA did not change basal paw responses to mechanical, heat, or cold stimuli on the ipsilateral side of sham mice (Figs. 3C-E) . Premicroinjection of control negative siRNA did not alter CCI-caused enhanced paw withdrawal responses to mechanical, heat, and cold stimuli on the ipsilateral side (Figs. 3C-E) . No significant differences in paw withdrawal responses were seen between the vehicle-microinjected and negative control siRNA-microinjected groups (Figs. 3C-E) . Basal paw withdrawal responses to mechanical, heat, and cold stimuli on the contralateral side (Figs. 3F and G) and locomotor activities (supplemental Table 2 , available at http://links.lww.com/ PAIN/A664) were not changed by premicroinjection of either siRNA or vehicle.
We also determined whether premicroinjection of OCT1 siRNA affected CCI-caused dorsal horn central sensitization, as revealed by the increases in the levels of p-ERK1/2 (a marker for neuronal hyperactivation) and GFAP (a marker for astrocyte protein (B) in the ipsilateral L4/5 DRG on day 5 after CCI or sham surgery. n 5 3 biological replicates (6 rats) per group. One-way ANOVA followed by the post hoc Tukey test. *P , 0.05 or **P , 0.01 vs the vehicle (Veh) plus sham group. #P , 0.05 vs the vehicle plus CCI group. (C-G) Effect of premicroinjection of OCT1 siRNA (Si), vehicle (Veh), or negative control siRNA (NC) into the ipsilateral L4/5 DRG on paw withdrawal threshold to mechanical stimulation (C and F), paw withdrawal latency to heat stimulation (D and G), and paw withdrawal latency to cold stimulation (E) on the ipsilateral (C-E) and contralateral (F and G) sides at the different days after CCI or sham surgery. n 5 5 rats per group. Two-way ANOVA followed by the post hoc Tukey test. **P , 0.01 vs the vehicle plus CCI group at the corresponding time point. (H) Effect of premicroinjection of OCT1 siRNA (Si) or vehicle (Veh) into the ipsilateral L4/5 DRG on CCI-caused increases in the phosphorylation of ERK1/2 and expression of GFAP in the ipsilateral L4/5 dorsal horn on day 5 after CCI or sham surgery. Left: Representative Western blots; Right: A statistical summary of densitometric analysis. n 5 3 biological replicates (6 rats) per group. One-way ANOVA followed by the post hoc Tukey test. *P , 0.05 or **P , 0.01 vs the corresponding vehicle plus sham group. ##P , 0.01 vs the corresponding vehicle plus CCI group. CCI, chronic constriction injury; DRG, dorsal root ganglion; GFAP, glial fibrillary acidic protein.
hyperactivation) in the dorsal horn. 7, 8, 25, 26 Consistent with previous studies in the SNL-induced neuropathic pain model, 8, 25, 26 the levels of p-ERK1/2 (but not total ERK1/2) and GFAP were markedly increased in the ipsilateral L4/5 dorsal horn from the vehicle-microinjected CCI rats compared with those from the vehicle-microinjected sham rats (Fig. 3H) . These increases were absent in the OCT1 siRNA-microinjected CCI rats (Fig. 3H) .
Effect of blocking increased dorsal root ganglion OCT1 on the maintenance of chronic constriction injury-caused pain hypersensitivity
We further examined whether DRG OCT1 was required for the maintenance of CCI-caused pain hypersensitivities. Vehicle or siRNA was given 7 days after CCI, at this time point when CCIinduced pain hypersensitivity was robust and stable. Postadministration of OCT1 siRNA, but not control negative siRNA, attenuated CCI-caused enhanced paw withdrawal responses to mechanical, heat, and cold stimuli on the ipsilateral side on days 7 till day 14 after CCI (Figs. 4A-C) . In the vehicle-treated group, CCI led to a robust decrease in rat PWT to mechanical stimulation and PWL to heat or cold stimulation on the ipsilateral side during the maintenance period (Figs. 4A-C) . OCT1 siRNA markedly reversed these decreases compared with the vehicle or control negative siRNA-treated group on days 12 and 14 after CCI (Figs. 4A-C) . As expected, postmicroinjection of vehicle, OCT1 siRNA, or control negative siRNA did not alter basal paw withdrawal responses on the contralateral side (Figs. 4D and E) .
Effect of dorsal root ganglion OCT1 overexpression on nociceptive thresholds in naive rats
We then determined whether mimicking the CCI-caused increase in DRG OCT1 via microinjection of AAV5 that expresses rat Oct1 full-length mRNA (AAV5-OCT1) into the unilateral L4/5 DRG changed the nociceptive thresholds in naive rats. As expected, the amounts of OCT1 mRNA and protein in the microinjected DRG from the AAV5-OCT1-injected rats were increased significantly compared with those from the control AAV5-EGFP-injected group 8 weeks after microinjection (Figs. 5A  and B) . Microinjection of AAV5-OCT1, but not control AAV5-EGFP, produced the augmented paw withdrawal responses to mechanical, heat, and cold stimuli on the ipsilateral side (Figs. 5C-E). These enhanced responses occurred between 3 and 6 weeks and lasted for at least 8 weeks (Figs. 5C-E) . This phenomenon is in the line with the fact that AAV5 requires 3 to 4 weeks to become expressed and persists for at least 3 months. 4, 6 On the contralateral side, the basal paw withdrawal responses were not altered in either virus-microinjected rat (Figs. 5F and G).
Participation of OCT1 in chronic constriction injury-induced increase in DNMT3a and downregulation of MOR and Kv1.2 in the injured dorsal root ganglion
How is OCT1, a transcription factor in the DRG, involved in CCIcaused pain hypersensitivity? It is evident that OCT1 promotes Dnmt3a gene transcription in DRG neurons. 20, 26 Given that the increased DNMT3a in the injured DRG participates in neuropathic pain genesis through downregulation of DRG MOR and Kv1.2, 20, 26 we predicted that OCT1 contributed to neuropathic pain through DNMT3a/MOR/Kv1.2 pathway in the injured DRG. Like the fifth lumbar SNL, 20, 26 CCI led to the increases in the amounts of Dnmt3a mRNA and DNMT3a protein and the decreases in the levels of MOR and Kv1.2 mRNAs and proteins in the ipsilateral DRG 7 days after CCI in the vehicle-or control negative siRNA-microinjected rats (Figs. 6A and B) . These changes were not seen in the OCT1 siRNA-microinjected CCI rats (Figs. 6A and B) . Microinjection of OCT1 siRNA did not markedly change the basal amounts of Dnmt3a, Oprm1, and Kcna2 mRNAs and their corresponding proteins in the injected DRG of sham rats (Figs. 6A and B) . In addition, DRG microinjection of AAV5-OCT1 produced the increases in the levels of Dnmt3a mRNA and its protein DNMT3a and the reductions in the levels of Oprm1 mRNA, Kcna2 mRNA, and their encoding proteins compared with the AAV5-EGFP-microinjected group in the injected DRG of naive rats 8 weeks after microinjection (Figs. 6C and D) . The double-labeled immunostaining assay showed the coexpression of OCT1 with MOR or Kv1.2 in some DRG neurons (Fig. 6E) .
Effect of blocking increased dorsal root ganglion OCT1 on morphine analgesia under chronic constriction injury-caused neuropathic pain conditions
We finally examined whether blocking the increase in DRG OCT1 improved morphine analgesia after CCI. Consistent with previous studies, 7, 25 analgesia caused by systemically s.c. injection of morphine 3 days after CCI was markedly decreased compared with that 3 days after sham surgery on the ipsilateral side of the vehicle-treated group (Fig. 7A) . This decrease was rescued on the ipsilateral side of the OCT siRNA-treated group (Fig. 7A) . As predicted, systemic morphine injection led to significant analgesic effects on the contralateral side of all treated rats (Fig. 7A) . To further define whether antinociceptive effect in the OCT siRNAmicroinjected rats was mediated by DRG MOR, we i.p. injected methylnaltrexone, a peripheral MOR antagonist, into the microinjected rats 4 days after CCI or sham surgery. The OCT1 siRNAmicroinjected rats displayed complete attenuation of CCI-caused thermal hyperalgesia on the ipsilateral side before systemic methylnaltrexone administration (Fig. 7B) . Nevertheless, this effect was absent 30 minutes after i.p. injection of methylnaltrexone (Fig. 7B) . Systemic methylnaltrexone at the dose used failed to alter basal paw withdrawal responses on the ipsilateral side of the vehicle-microinjected sham groups and on the contralateral side of all microinjected groups (Figs. 7B and C).
Discussion
Chronic constriction injury-caused neuropathic pain in the preclinical animal model imitates neuropathic pain caused by some surgeries (such as breast surgery, thoracotomy, limb amputation, and cardiac surgery) in the clinic. 5, 23 Investigating how CCI leads to pain hypersensitivities may provide a new avenue for the management of this disorder. Here, we report that blocking increased OCT1 in the injured DRG alleviated CCIcaused mechanical allodynia, heat hyperalgesia, and cold allodynia during the induction and maintenance periods through rescuing DNMT3a-triggered downregulation of DRG MOR and Kv1.2. Given that acute pain and locomotor activity were not 6,7 the expression of OCT1 can be regulated after peripheral nerve injury. We revealed that CCI produced a significant and time-dependent increase of OCT1 protein in the ipsilateral DRG, an observation that is in the line with our previous study in an SNL model. 26 This suggests that OCT1 is activated at the transcriptional and/or translational levels after peripheral nerve injury. Although the detailed mechanisms by which CCI causes the transcriptional and translational activations of Oct1 gene are still elusive, these activations are likely related to epigenetic modifications, posttranslational modifications, or increases in RNA stability and/or triggered by other transcription factors under neuropathic pain conditions. These possibilities merit investigation in our future studies.
In this study, we used OCT1 siRNA to investigate the role of DRG OCT1 in neuropathic pain. We found that microinjection of OCT1 siRNA into the ipsilateral DRG attenuated the CCI-caused increase in DRG OCT1 and pain hypersensitivities during the development and maintenance periods. Given that OCT1 siRNA did not affect acute pain and locomotor functions, this suggests the specificity and selectivity of OCT1 siRNA effects. Interestingly, microinjection of OCT1 siRNA into the DRG failed to reduce basal expression of OCT1 in the sham DRG, although this siRNA was effective in the cultured DRG. The mechanism by which OCT1 siRNA did not affect basal OCT1 expression in vivo is unknown but could be due to its low expression in the DRG under normal conditions. In addition, the remaining OCT1 mRNA after its knockdown may have a high translational efficacy, which likely maintains normal level of basal OCT1 protein in the sham DRG.
The increased OCT1 in the injured DRG may participate in the CCI-caused pain hypersensitivities by triggering Dnmt3a gene transcription in the injured DRG. The DNMT3a methylates DNA at some CpG locations of the promoter and 5-untranslated regions of the genes, resulting in gene transcription repression through physically blocking the interaction of transcriptional factors and/or functioning as docking locations for transcriptional repressors/ corepressors. 9, 17, 18, 22 DNMT3a is required for nerve injury-caused reduction of Kv1.2 and MOR in the injured DRG. 20, 26 Given that the reduction of DRG Kv1.2 and MOR contributes to neuropathic pain genesis, 4, 8, 10, 20, 26, 27 the increased DNMT3a in the injured DRG is believed as a trigger of neuropathic pain. The data from the present study and previous work 26 demonstrated that OCT1 was required for nerve injury-caused transcriptional activation of DRG Dnmt3a gene, resulting in an increase in DNMT3a protein and in the reductions in MOR and Kv1.2 in the injured DRG. Moreover, OCT1 coexpresses with DNMT3a, MOR or Kv1.2, and DNMT3a with MOR or Kv1.2 in individual DRG neurons. 26 Therefore, the antinociceptive effect produced by blocking the CCI-caused increase in DRG OCT1 likely results from the failure to transcriptionally activate Dnmt3a gene in the injured DRG after CCI. Without an increase in DNMT3a protein, no alterations would occur in MOR and Kv1.2 expression, their gated neuronal excitability in the injured DRG neurons, and subsequent central sensitization in the ipsilateral dorsal horn. Indeed, blocking the CCI-caused increase of DRG OCT1 attenuated the CCI-caused increases in markers for central sensitization in the ipsilateral L4/5 dorsal horn and pain hypersensitivities. In addition, the antinociceptive effect produced by this blocking on CCI-caused pain hypersensitivities was abolished by antagonizing peripheral MOR. Given that the promoter regions of Oprm1 (encoding MOR) and Kcna2 (encoding Kv1.2) do not contain the consensus binding motif of OCT1, Figure 7 . Blocking CCI-caused increase in OCT1 in the injured DRG improves MOR-mediated analgesia under CCI-caused neuropathic pain conditions. (A) Effect of premicroinjection of OCT1 siRNA or vehicle (Veh) into the unilateral L4/5 DRG on morphine analgesia on the ipsilateral and contralateral sides 3 days after CCI or sham surgery. n 5 5 rats/group. Two-way ANOVA followed by the post hoc Tukey test. **P , 0.01 vs the corresponding vehicle plus sham group. #P , 0.05 vs the corresponding vehicle plus CCI group. (B and C) Effect of intraperitoneal injection of methylnaltrexone (M) on the OCT1 siRNA-produced antinociceptive effect 4 days after CCI or sham surgery on the ipsilateral side. n 5 5 rats/group. Two-way ANOVA followed by the post hoc Tukey test. **P , 0.01 vs the vehicle plus sham group at the corresponding time point. #P , 0.05 vs the vehicle plus CCI group at the corresponding time point. CCI, chronic constriction injury; DRG, dorsal root ganglion; MAPE, maximal possible analgesic effect. 
